Last updated: 2024-05-27

Checks: 0 1

Knit directory: combiDLBCL/analysis/

This reproducible R Markdown analysis was created with workflowr (version 1.7.0). The Checks tab describes the reproducibility checks that were applied when the results were created. The Past versions tab lists the development history.

Repository version: no version control

Tracking code development and connecting the code version to the results is critical for reproducibility. To start using Git, open the Terminal and type git init in your project directory.

This project is not being versioned with Git. To obtain the full reproducibility benefits of using workflowr, please see ?wflow_start.

Drug screen data from Lea:

Part 1: Quality assessment

html link

Part 2: Single agent effect analysis

html link

This report includes the exploratory analysis (PCA, hierarchical clustering), genomic associations, consensus clustering and multi-omics association analysis of the single agent screen data.

Part 3: Analysis of the combinatorial effect between CHP and Pola

html link

Part 4: Analysis of the combinatorial effect of all drugs estimated by simple Bliss independence model

html link

Part 5: Analysis of the combinatorial effect of all drug estimated by bayesynergy method

html link

Part 6: Integrative analysis using MOFA

html link

Part 7: Compare the signature of CHP resistant and sensitive cell lines (using binary response group)

html link

Part 8: Compare the signature of Doxorubicin resistant and sensitive DLBCL cell lines (using continous response variable)

html link

Drug screen data from Antonia

Analyses of the DLBCL combinatorial drug screen and multi-omic data

Drug screen data from Lea:

Part 1: Quality assessment

Part 2: Single agent effect analysis

Part 3: Analysis of the combinatorial effect between CHP and Pola

Part 4: Analysis of the combinatorial effect of all drugs estimated by simple Bliss independence model

Part 5: Analysis of the combinatorial effect of all drug estimated by bayesynergy method

Part 6: Integrative analysis using MOFA

Part 7: Compare the signature of CHP resistant and sensitive cell lines (using binary response group)

Part 8: Compare the signature of Doxorubicin resistant and sensitive DLBCL cell lines (using continous response variable)

Part 9: Compare the difference between TP53 mutational signature and Doxorubicine resistant signature to identify pathways related to Doxorubicine resistance

Drug screen data from Antonia

Data preprocessing

Single-agent analysis

Combinatroial analysis based on Bliss model

Seahore data analysis